Ben-Shlomo Anat
Pituitary Center, Endocrinology, Diabetes and Metabolism Division, Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 3066, Los Angeles, CA 90048, USA.
Endocrinol Metab Clin North Am. 2015 Mar;44(1):35-41. doi: 10.1016/j.ecl.2014.10.004. Epub 2014 Nov 4.
Somatostatin receptor ligands (octreotide and lanreotide) are currently first-line pharmacotherapy for patients with acromegaly in whom surgery fails to control the disease or cannot be considered. The efficacy of a new pan somatostatin receptor ligand, pasireotide, has been investigated as a potential treatment of acromegaly. Several clinical trials showed disease-remission with pasireotide in one-third of patients and some octreotide-resistant patients were responsive to pasireotide. Pasireotide can likely be used for patients with suboptimal response or resistance to treatment with the approved maximal doses of octreotide long-acting release (LAR) or lanreotide Autogel; however, the development or exacerbation of diabetes mellitus is of concern.
生长抑素受体配体（奥曲肽和兰瑞肽）目前是肢端肥大症患者的一线药物治疗方法，这些患者手术无法控制病情或不适合进行手术。新型全生长抑素受体配体帕西瑞肽作为肢端肥大症的潜在治疗方法，其疗效已得到研究。多项临床试验表明，三分之一的患者使用帕西瑞肽后病情缓解，一些对奥曲肽耐药的患者对帕西瑞肽有反应。帕西瑞肽可能适用于对已批准的最大剂量奥曲肽长效释放（LAR）或兰瑞肽Autogel治疗反应欠佳或耐药的患者；然而，糖尿病的发生或加重令人担忧。
